

**DETECTION OF LOW DENSITY LIPOPROTEIN
RECEPTOR GENE MUTATIONS IN PATIENTS WITH
FAMILIAL HYPERCHOLESTEROLAEMIA**

RAFEZAH BINTI RAZALI

**INSTITUTE OF BIOLOGICAL SCIENCES
FACULTY OF SCIENCE
UNIVERSITY OF MALAYA
KUALA LUMPUR**

2011

**DETECTION OF LOW DENSITY LIPOPROTEIN
RECEPTOR GENE MUTATIONS IN PATIENTS WITH
FAMILIAL HYPERCHOLESTEROLAEMIA**

RAFEZAH BINTI RAZALI

Dissertation submitted in partial fulfilment of
the requirement for the degree of
Master of Biotechnology

**INSTITUTE OF BIOLOGICAL SCIENCES
FACULTY OF SCIENCE
UNIVERSITY OF MALAYA
KUALA LUMPUR**

2011

ABSTRACT

Familial hypercholesterolaemia (FH) is an autosomal dominant inherited disorder of lipoprotein metabolism associated with premature coronary artery disease (CAD). Extrapolating the prevalence of heterozygous FH in western populations into Malaysian population, it would be estimated that about 50,000 Malaysians would be affected and at risk of developing premature CAD. Mutations of the low density lipoprotein receptor (LDLR) gene are the most frequent cause of FH but its genetic profiles in the Asian population has been poorly characterised. Therefore, in this study, the screening and characterisation of the LDLR gene mutations and its polymorphisms among patients with clinical diagnosis of FH were compared to normocholesterolaemic controls. Cross sectional study involving 74 FH patients (50 Malays & 24 Chinese) and 77 age-matched normocholesterolaemic controls were recruited. Diagnosis of FH was based on Simon Broome Register criteria. Blood samples were collected, serum and plasma were separated, stored and analysed for fasting serum lipids, glucose, renal profile, liver function tests and thyroid function test by standard automated laboratory techniques. Whole blood in EDTA tubes were collected and stored in -80 °C until DNA extractions were performed using a commercial kit. Genomic DNA purity was determined using a spectrophotometer. Gene amplification by polymerase chain reaction (PCR) was employed to amplify all exons (exon 1 – 18) and the promoter region of the LDLR gene. Mutation screening analysis was performed by denaturing high performance liquid chromatography (DHPLC). Samples showing heteroduplexes profiles by DHPLC were sequenced to confirm the location and nature of mutations using Sanger sequencing method. The present study detected five LDLR variants among 46 (62.2%) of FH patients in intron 3, exon 5, 9, 10 and 12 using DHPLC. Three different types of LDLR mutations were confirmed by Sanger sequencing in 6 out of 46 (13%) clinically-diagnosed FH patients. The identified mutations were in intron 3 (g.313+1G>A) of a FH patient of Chinese ethnicity, exon 5 (g.763T>A; C234S) of four FH patients of a Malay family and exon 9 (g.1216C>T; R385W) of a FH patient of Chinese ethnicity. Of the identified Malay family members, a homozygote and three heterozygotes for LDLR C234S mutation were found. Other variants identified were in exons 10 (g.1413G>A) and 12 (g.1773T>C). However, both variants in exons 10 and 12 did not cause amino acid change (arginine (R) at codon 450 [AGG>AGA] and proline (N) at codon 570 [AAT>AAC]) respectively. In conclusion, the present work of employing molecular screening using DHPLC has been successfully optimised to detect the LDLR gene mutations. Combined with the clinical diagnosis criteria, the use of DNA-based screening method plays an important role in the definitive diagnosis of FH.

ABSTRAK

Hiperkolesterolemia familial (FH) adalah penyakit metabolisma lipoprotein keturunan yang diwariskan secara autosomal dominan dan mengaruh kepada peningkatan risiko penyakit arteri koronari pramatang. Menggunakan prevelan pada populasi di negara-negara Barat, dianggarkan seramai 50,000 penduduk Malaysia menghidap penyakit FH dan mempunyai risiko penyakit arteri koronari pramatang. Mutasi pada gen reseptor lipoprotein berketumpatan rendah (LDLR) merupakan punca utama penyakit FH. Walaubagaimanapun, pengenalpastian profil genetik penyakit ini di negara-negara Asia adalah kurang meluas. Kajian hirisan lintang ini dijalankan bagi menyaring dan mengenaldpasti mutasi gen LDLR di kalangan 74 pesakit FH berbanding 77 subjek yang mempunyai aras kolesterol yang normal. Diagnosis penyakit FH dibuat berdasarkan kriteria Simon Broome. Sampel darah telah diambil untuk ujian aras kolesterol, aras glukosa, fungsi buah pinggang, fungsi hepar, fungsi kelenjar tiroid dan pengekstrakan asid deoksiribonukleik (DNA). Pengekstrakan DNA dari sampel darah dibuat dengan menggunakan kit pengekstrakan DNA komersial dan ketulenannya diukur menggunakan spektrofotometer. Amplifikasi kesemua ekson dan kawasan promoter pada gen LDLR dibuat menggunakan reaksi rantai polimerase (PCR). Penyaringan mutasi gen LDLR dibuat menggunakan teknik *denaturing high performance liquid chromatography* (DHPLC). Penjujukan DNA dilakukan terhadap sampel-sampel DNA yang menunjukkan profil *heteroduplexes* semasa penyaringan menggunakan DHPLC bagi mengesahkan kehadiran dan jenis mutasi. Menggunakan teknik DHPLC, lima jenis variasi gen LDLR telah dikenaldpasti di kalangan 46 (62.2%) pesakit FH iaitu terletak di kawasan intron 3, ekson 5,9,10 dan 12. Tiga jenis mutasi telah disahkan melalui teknik penjujukan DNA pada 6 daripada 46 (13%) pesakit FH. Mutasi yang dikenaldpasti adalah di kawasan intron 3 (g.313+1G>A) pada seorang pesakit bangsa Cina, mutasi pada ekson 5 (g.763T>A; C234S) di kalangan empat orang ahli keluarga bangsa Melayu dan mutasi pada ekson 9 (g.1216C>T; R385W) pada seorang pesakit bangsa Cina. Di kalangan empat orang ahli keluarga yang mempunyai mutasi pada ekson 5, seorang adalah homozigot dan tiga orang lagi merupakan heterozigot. Variasi gene LDLR lain melibatkan ekson 10 dan ekson 12 tetapi variasi ini tidak menyebabkan perubahan di peringkat asid amino. Sebagai kesimpulan, teknik DHPLC telah berjaya dibangunkan secara optimum sebagai kaedah saringan mutasi gen LDLR pada pesakit FH. Teknik analisa DNA memainkan peranan penting dalam pengenalpastian jenis mutasi pada penyakit FH disamping diagnosis menggunakan ciri-ciri klinikal.

ACKNOWLEDGEMENT

Alhamdulillah, great thanks to Allah and His blessing for giving me the strength and health to complete this study.

This dissertation would not have been possible without the guidance and the help of several individuals who in one way or another contributed and extended their valuable assistance in the preparation and completion of this study.

I would like to express my most esteemed gratitude to Dr Noraida Ismail (Institute of Biological Sciences, Faculty of Science, University of Malaya), Dr Sahilah Abdul Mutalib (Faculty of Science and Technology, Universiti Kebangsaan Malaysia), Professor Dr. Hapizah Mohd. Nawawi, Associate Professor Dr Gabriele Froemming and Dr Hoh Boon Peng from Faculty of Medicine, Universiti Teknologi MARA for their guidance, support and encouragement throughout this project and thesis writing. I would also like to extend my heartfelt appreciation to Dr Thuhairah Hasrah Abdul Rahman, Pn Suhaila Muid, Cik Azlina A. Razak, Cik Suhana Hamzan and all the laboratory staffs and postgraduate students both in Institute Medical Molecular Biotechnology (IMMB) and Research Laboratory with whom I had the privilege of working with.

I would like to extend my heartfelt appreciation to my beloved parents, husband and daughter who understood my long hours away from home and gave me their prayers, moral support and motivation to complete this project and thesis writing. Finally, I would like to convey my regards and blessings to all of those who supported me in any respect during the completion of this study.

TABLE OF CONTENTS

	Page
Abstract	ii
Abstrak	iii
Acknowledgement	iv
Contents	v
List of Figures	viii
List of Tables	xi
List of Abbreviations	xii
CHAPTER ONE	INTRODUCTION
1.1 Background of Study	1
1.2 Objectives of Study	5
1.3 Significance of the Study	6
CHAPTER TWO	LITERATURE REVIEW
2.1 Human Cholesterol Metabolism	8
2.2 Hypercholesterolaemia	13
2.3 Familial Hypercholesterolaemia	19
2.3.1 Clinical Signs of Familial Hypercholesterolaemia Patients	21
2.3.2 Clinical Diagnosis of Familial Hypercholesterolaemia	22
2.3.3 Management and Treatment of Familial Hypercholesterolaemia	26
2.4 Low-density Lipoprotein Receptor	28
2.5 Mutation Detection Techniques	34
2.6 Denaturing High Performance Liquid Chromatography (DHPLC)	35

CHAPTER THREE METHODOLOGY

3.1 Study Participants and Design	42
3.2 Anthropometry Measurements and Data Collection	42
3.3 Sample Collection	43
3.4 Biochemical Analysis	43
3.4.1 Fasting Plasma Glucose	44
3.4.2 Fasting Serum Lipid	44
3.4.3 Liver Function Test	45
3.4.4 Renal Profile	46
3.4.5 Thyroid Function Test	47
3.5 Molecular Analysis	47
3.5.1 DNA Extraction	47
3.5.2 DNA Quantification	48
3.5.3 Amplification of LDLR gene by Polymerase Chain Reaction	48
3.5.3.1 PCR Set Up	50
3.5.3.2 Analysis of PCR Products	52
3.5.3.3 PCR Products Purification	54
3.5.4 Denaturing High Performance Liquid Chromatography	54
3.5.5 DNA Sequencing	55
3.5.5.1 Ethanol/Ammonium acetate precipitation	56
3.6 Statistical Analysis	56

CHAPTER FOUR RESULTS

4.1 Biochemical Presentation of FH Patients	57
4.2 Clinical Presentation of FH Patients	59
4.3 DNA Extraction Results	60

4.4 PCR Results	63	
4.5 DHPLC Results	85	
4.6 Sequencing Results	94	
CHAPTER FIVE	DISCUSSION	109
5.1 DNA Extraction	109	
5.2 Amplification of LDLR gene by PCR	110	
5.3 Mutation screening by Denaturing High Performance Liquid Chromatography	113	
5.4 Mutation identification of LDLR Gene by DNA Sequencing	116	
CHAPTER SIX	CONCLUSION	120
BIBLIOGRAPHY	121	
APPENDICES		
Appendix – A: Simon Broome Register Criteria for Diagnosis of FH	142	
Appendix – B: Patient Consent Form	143	
Appendix – C: Patient Data Collection Sheet	157	
Appendix – D: DHPLC temperature profiles	159	
Appendix – E: List of Publications	160	
Appendix – F: Posters Presentation	161	

LIST OF FIGURES

	Page
Figure 1.1: Death by causes in all ages among Malaysians in 2002.	2
Figure 2.1.1: Overview of cholesterol metabolism in humans.	10
Figure 2.1.2: Schematic illustration of the uptake of LDL particles by the LDLR.	12
Figure 2.2.1: Relative risk of coronary artery disease mortality versus baseline serum cholesterol concentrations.	15
Figure 2.2.2: Simplified schematic diagram of cholesterol biosynthesis pathway.	18
Figure 2.4.1: Schematic diagram illustrates the LDL receptor pathway.	29
Figure 2.4.2: Schematic diagram represents the domain structure of the human LDL receptor and its relation to the exon organisation of the LDLR gene.	30
Figure 2.4.3: Ideogram showing the location of LDLR gene on chromosome 19 at 19p13.1-p13.3.	31
Figure 2.6.1: Schematic of DHPLC system showing the placement of hardware and the flow direction of the mobile phase.	38
Figure 2.6.2: Use of DHPLC to separate homoduplexes and heteroduplexes	39
Figure 2.6.3: Melting curve of a DNA fragment at different temperature profile	40
Figure 3.1: Chip priming station of Agilent Bionalyser	52
Figure 3.2: Agilent Bioanalyser System for PCR product analysis	53
Figure 4.2.1: Clinical presentations of FH patients.	59
Figure 4.3.1: Genomic DNA quantitation using spectrophotometer	62
Figure 4.4.1: Amplification of Promoter region of LDLR gene by PCR.	63
Figure 4.4.2: Amplification of Exon 1 of LDLR gene by PCR.	64
Figure 4.4.3: Amplification of Exon 2 of LDLR gene by PCR.	65
Figure 4.4.4: Amplification of Exon 3 of LDLR gene by PCR.	66

Figure 4.4.5: Amplification of Exon 4-5' of LDLR gene by PCR.	67
Figure 4.4.6: Amplification of Exon 4-mid of LDLR gene by PCR.	68
Figure 4.4.7: Amplification of Exon 4-3' of LDLR gene by PCR.	69
Figure 4.4.8: Amplification of Exon 5 of LDLR gene by PCR.	70
Figure 4.4.9: Amplification of Exon 6 of LDLR gene by PCR.	71
Figure 4.4.10: Amplification of Exon 7 of LDLR gene by PCR.	72
Figure 4.4.11: Amplification of Exon 8 of LDLR gene by PCR.	73
Figure 4.4.12: Amplification of Exon 9 of LDLR gene by PCR.	74
Figure 4.4.13: Amplification of Exon 10-5' of LDLR gene by PCR.	75
Figure 4.4.14: Amplification of Exon 10-3' of LDLR gene by PCR.	76
Figure 4.4.15: Amplification of Exon 11 of LDLR gene by PCR.	77
Figure 4.4.16: Amplification of Exon 12 of LDLR gene by PCR.	78
Figure 4.4.17: Amplification of Exon 13 of LDLR gene by PCR.	79
Figure 4.4.18: Amplification of Exon 14 of LDLR gene by PCR.	80
Figure 4.4.19: Amplification of Exon 15 of LDLR gene by PCR.	81
Figure 4.4.20: Amplification of Exon 16 of LDLR gene by PCR.	82
Figure 4.4.21: Amplification of Exon 17 of LDLR gene by PCR.	83
Figure 4.4.22: Amplification of Exon 18 of LDLR gene by PCR.	84
Figure 4.5.1: DHPLC Chromatogram profile of standards materials and blank run	85
Figure 4.5.2: Graph absorbance (mV) against time (minutes) of exon 3	87
Figure 4.5.3: DHPLC Chromatogram profile of exon 3	88
Figure 4.5.4: DHPLC Chromatogram profile of exon 5 of LDLR.	89
Figure 4.5.5: DHPLC Chromatogram profile exon 9 of LDLR.	90
Figure 4.5.6: Graph absorbance (mV) against time (minutes) of exon 10	91
Figure 4.5.7: DHPLC Chromatogram profile of exon 10 of LDLR	92
Figure 4.5.8: DHPLC Chromatogram profile of exon 12 of LDLR	93

Figure 4.6.1: Sequence profile of intron 3 of LDLR	97
Figure 4.6.2: Sequence profile of exon 5 of LDLR in homozygous FH patient	99
Figure 4.6.3: Sequence profile of exon 5 of LDLR in heterozygous FH patient	100
Figure 4.6.4: Sequence profile of exon 5 showing nucleotide substitution	101
Figure 4.6.5: Sequence profile of exon 5 of LDLR showing C234S mutation	102
Figure 4.6.6: Sequence profile exon 9 of LDLR in heterozygous FH patient	104
Figure 4.6.7: Sequence profile of exon 10 of LDLR	106
Figure 4.6.8: Sequence profile of exon 12 of LDLR	108

LIST OF TABLES

	Page
Table 1.1: Modifiable and non-modifiable coronary risk factors.	3
Table 2.3.2: The Simon Broome Register Group Diagnostic Criteria.	23
Table 2.3.2: The Simon Broome Register Group Diagnostic Criteria.	24
Table 2.3.3: The Dutch Lipid Clinic Network Diagnostic Criteria.	25
Table 3.1: List of primers sequence for amplification of LDLR gene.	49
Table 3.2: PCR master mixture for amplification of LDLR gene	50
Table 3.3: PCR protocols for the amplification of LDLR gene for promoter region and all exons with exception of exon 16	51
Table 3.4: The PCR conditions for amplification of LDLR gene for exon 16	51
Table 4.1.1: Biochemical presentation of FH patients	58
Table 4.1.2: Concentration and purity of genomic DNA	86
Table 4.5.1: FH patient samples showing disease-causing variant by DHPLC	91
Table 4.6.1: Results of DNA sequence analysis	94
Table 4.6.2: Effects of LDLR variants on fasting serum lipid profile of affected FH patients	95

LIST OF ABBREVIATIONS

APOB	Apolipoprotein B-100
BP	Blood pressure
bp	base pair
BMI	Body mass index
cDNA	Complementary DNA
CVD	Cardiovascular disease
CAD	Coronary artery disease
CETP	Cholesteryl ester transfer protein
DBP	Diastolic blood pressure
DGGE	Denaturing gradient gel electrophoresis
DHPLC	Denaturing high performance liquid chromatography
DNA	Deoxyribonucleic acid
dNTPs	Deoxynucleotide triphosphates
ddNTPs	Dideoxynucleotide triphosphates
EDTA	Ethylenediaminetetraacetic acid
FH	Familial hypercholesterolaemia
gDNA	Genomic DNA
HDL-c	High density lipoprotein
HMG-CoA	3-Hydroxy-3-methyl-glutaryl-CoA
LDL-c	Low density lipoprotein
LDLR	Low density lipoprotein receptor
LPL	Lipoprotein lipase
LRP	LDL-receptor like protein

MLPA	Multiplex ligation-dependent probe amplification
PCSK9	Proprotein convertase subtilisin/kexin type 9
PCR	Polymerase chain reaction
SBP	Systolic blood pressure
SCAP	Sterol cleavage-activating protein
SNPs	Single Nucleotide Polymorphisms
SREBP	Sterol regulatory element binding protein-2
SSCP	Single strand conformation polymorphism
TC	Total cholesterol
TG	Triglycerides
T _m	Melting Temperature
VLDL	Very low density lipoprotein
WHR	Waist-to-hip ratio